Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples